Apotex Corp. Launches Brimonidine Tartrate Ophthalmic Solution, 0.1% in the United States
Sep 5, 2023Apotex Corp. Launches Brimonidine Tartrate Ophthalmic Solution, 0.1% in the United States
Weston, Florida (September 5, 2023) – Apotex Corp. has released its latest ophthalmic product in the United States, announcing today that brimonidine tartrate ophthalmic solution, 0.1% is now available.
Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
“Open-angle glaucoma impacts over 2.7 million Americans, and millions more have ocular hypertension. Bringing this product to market will make a real difference for these patients, who depend on this medicine to preserve their vision,” says Peter Hardwick, President, Apotex Corp.
“We’re excited to be able to offer this high-quality, cost-saving option to prescribers and patients across the country.”
Prescribing information can be found at https://www.apotex.com/products/us/downloads/pre/brim_opso_0.1_ins.pdf.
About Apotex Corp.
Apotex Corp. is a US based company, headquartered in Weston, Florida. It and its global affiliates are leaders in generic pharmaceuticals and biosimilars and are committed to supplying patients with a broad portfolio of high-quality, affordable medicines covering all major therapeutic areas.
-30-
All media enquiries :
Jordan Berman
Vice-President, Global Corporate Affairs
Apotex Inc.
[email protected]
Mobile: 647-272-2287
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Nov 17, 2026
Apotex launches Axitinib Tablets in the U.S., the first generic version of INLYTA®
TORONTO, ON, November 17, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX) today announced the U.S. launch of Axitinib Tablets, 1 mg and 5 mg, the first generic version on INLYTA ®, a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
-
Aug 12, 2026
Apotex Announces First Quarter 2027 Results
TORONTO, ON, August 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada's largest pharmaceutical company, today announced its financial and operating results for the three months ended June 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.
-
Jul 17, 2026
Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement
Toronto, ON, July 16, 2026. Apotex Health Corp ("Apotex" or the "Company") (TSX: APTX) today announced the successful completion of an amended and restated credit agreement ("Amended Credit Agreement"), establishing a financing framework aligned with the Company's evolution as a publicly traded, investment-grade-rated issuer.